TheEdgeResearch
Home / Stocks / ZURA

Zura Bio Limited (ZURA)

NASDAQ Healthcare Biotechnology
$0.93 ▼ -2.30%
Market Cap
$89.6M
Sector
Healthcare
Industry
Biotechnology
Beta
-0.04
52-Wk Range
0.919-7.44
CEO
Sandeep C. Kulkarni
Country
US
Currency
USD

Zura Bio Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Henderson, NV, US. The stock last traded at $0.93, down 2.30% on the session, giving a market capitalisation of $89.6M. On trailing twelve-month figures it carries a trailing P/E of -0.83, a net margin of 0.0%. Its beta of -0.04 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.83
Price / Sales
0.00
Price / Book
0.67
EV / EBITDA
1.03
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
11.29
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
40
IPO date
2023-03-21
Headquarters
Henderson, NV, US
About Zura Bio Limited

Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.

Comparable companies

Zura Bio Limited is most often compared with the following Healthcare names:

AARDARCTASMBENTAFHTXIMRXNAUTPYXSSGMTTNYA
More research on ZURA
ZURA technical analysis ZURA TheEdge Score Compare against peers
Open full interactive analysis & DCF →